- >99,9%
- Detection rate
of Ninalia NIPT test
- 1
- Single blood sample
- 10
- Available from week 10
of pregnancy
- 5
- Results available
within 5 working days
- 95%
- Can minimize unnecessary invasive sampling by 95%
NIPT
Non-Invasive Prenatal screening Test for trisomies 13, 18 and 21
Non-invasive prenatal screening is an innovative genetic test designed for pregnant women with a risk of foetal trisomies 13, 18 or 21.
The test is based on the presence of foetal DNA in the maternal blood, combined with the development of a technology (Next Generation Sequencing) capable of counting all genetic material sequences in a maternal blood sample, making it possible to determine whether a trisomy is present in the foetus.
Rapid, reliable and safe, NIPT enables detection of trisomies 13, 18 and 21 while limiting reliance on invasive sampling (amniocentesis or puncture of chorionic villi).
Eurofins Biomnis in figures
As a French laboratory and European leader in specialised medical pathology testing, Eurofins Biomnis has been an expert in the new generation of DNA sequencing techniques for many years and has acquired extensive know-how in the areas of prenatal genetics and biology.
Experts in their fields, the qualified prenatal diagnostics biologists responsible for Ninalia NIPT at Eurofins Biomnis support prescribers, Laboratories and their patients in the implementation of this innovative genetic test.
- 1
- century of expertise in specialised biology
- 32 000
- medical biology tests every day
- 2 000
- Karyotypes performed
in 2016
- 45 000
- Ninalia tests performed
since october 2014
- 200 000
- Maternal serum markers tests performed
in 2016
